Immunol Cell Biol. 2007 Aug-Sep;85(6):490-4. Epub 2007 Jul 31.

Targeting toll-like receptors for drug development: a summary of commercial approaches.

Source

Biocomm Squared and Monash Institute of Medical Research, Monash University, Clayton, Victoria, Australia. gearing@biocommsquared.com.au

Abstract

Toll-like receptors (TLRs) play a fundamental role in recognizing infectious and noxious agents as well as products of tissue damage. They are capable of initiating both protective and damaging inflammatory and immune responses. Several biotechnology and pharmaceutical companies have programmes to develop new drugs that are either: agonists of TLRs to enhance immune responses against tumours and infectious agents, or to correct allergic responses; or antagonists designed to reduce inflammation due to infection or autoimmune disease. This article reviews the commercial approaches being undertaken to develop new TLR drugs.

PMID:: 17667933; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

Toll-Like Receptors

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Supplemental Content

Save items

Related citations in PubMed

Review [Responses with participation of toll-like receptors in protective immunity and in pathologic states]. [Ukr Biokhim Zh. 2008]
Review [Responses with participation of toll-like receptors in protective immunity and in pathologic states].
Skivka LM, Pozur VV. Ukr Biokhim Zh. 2008 May-Jun; 80(3):5-20.
Review Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. [Immunol Rev. 2007]
Review Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity.
Krieg AM, Vollmer J. Immunol Rev. 2007 Dec; 220:251-69.
Review Toll-like receptor modulators: a patent review (2006-2010). [Expert Opin Ther Pat. 2011]
Review Toll-like receptor modulators: a patent review (2006-2010).
Basith S, Manavalan B, Lee G, Kim SG, Choi S. Expert Opin Ther Pat. 2011 Jun; 21(6):927-44. Epub 2011 Mar 15.
Review Targeting toll-like receptor signaling pathways for design of novel immune therapeutics. [Curr Drug Discov Technol. 2008]
Review Targeting toll-like receptor signaling pathways for design of novel immune therapeutics.
Hong-Geller E, Chaudhary A, Lauer S. Curr Drug Discov Technol. 2008 Mar; 5(1):29-38.
Review Toll-like receptors as therapeutic targets in cystic fibrosis. [Expert Opin Ther Targets. 2008]
Review Toll-like receptors as therapeutic targets in cystic fibrosis.
Greene CM, Branagan P, McElvaney NG. Expert Opin Ther Targets. 2008 Dec; 12(12):1481-95.

See reviews... See all...

Cited by 7 PubMed Central articles

Review Association of Toll-like receptor signaling and reactive oxygen species: a potential therapeutic target for posttrauma acute lung injury. [Mediators Inflamm. 2010]
Review Association of Toll-like receptor signaling and reactive oxygen species: a potential therapeutic target for posttrauma acute lung injury.
Xiang M, Fan J, Fan J. Mediators Inflamm. 2010; 2010. Epub 2010 Jul 13.
Review Heat-labile enterotoxins as adjuvants or anti-inflammatory agents. [Immunol Invest. 2010]
Review Heat-labile enterotoxins as adjuvants or anti-inflammatory agents.
Liang S, Hajishengallis G. Immunol Invest. 2010; 39(4-5):449-67.
Review Targeting TLR/IL-1R signalling in human diseases. [Mediators Inflamm. 2010]
Review Targeting TLR/IL-1R signalling in human diseases.
Loiarro M, Ruggiero V, Sette C. Mediators Inflamm. 2010; 2010:674363. Epub 2010 Apr 8.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Targeting toll-like receptors for drug development: a summary of commercial appr...
Targeting toll-like receptors for drug development: a summary of commercial approaches.
Immunol Cell Biol. 2007 Aug-Sep ;85(6):490-4. Epub 2007 Jul 31 .

PubMed
Intratumoural injection of the toll-like receptor-2/6 agonist 'macrophage-activa...
Intratumoural injection of the toll-like receptor-2/6 agonist 'macrophage-activating lipopeptide-2' in patients with pancreatic carcinoma: a phase I/II trial.
Br J Cancer. 2007 Sep 3 ;97(5):598-604. Epub 2007 Jul 31 .

PubMed
D-cycloserine inhibits amygdala responses during repeated presentations of faces...
D-cycloserine inhibits amygdala responses during repeated presentations of faces.
CNS Spectr. 2007 Aug ;12(8):600-5.

PubMed
Cardiovascular disease under the influence of excess visceral fat.
Cardiovascular disease under the influence of excess visceral fat.
Crit Pathw Cardiol. 2007 Jun ;6(2):51-9.

PubMed
Infusion of stably immature monocyte-derived dendritic cells plus CTLA4Ig modula...
Infusion of stably immature monocyte-derived dendritic cells plus CTLA4Ig modulates alloimmune reactivity in rhesus macaques.
Transplantation. 2007 Jul 27 ;84(2):196-206.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: